Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by JPPOUGET
Group name EquipeJPP
Item Type Journal Article
Title Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)
Creator Van der Weijst et al.
Author Lotte Van der Weijst
Author Miguel E. Aguado-Barrera
Author David Azria
Author Patrick Berkovic
Author Pierre Boisselier
Author Erik Briers
Author Renée Bultijnck
Author Patricia Calvo-Crespo
Author Jenny Chang-Claude
Author Ananya Choudhury
Author Gilles Defraene
Author Sylvian Demontois
Author Alison M. Dunning
Author Rebecca M. Elliott
Author Dawn Ennis
Author Corinne Faivre-Finn
Author Marzia Franceschini
Author Sara Gutiérrez-Enríquez
Author Carsten Herskind
Author Daniel S. Higginson
Author Sarah L. Kerns
Author Kerstie Johnson
Author Meritxell Mollà
Author Maarten Lambrecht
Author Mónica Ramos
Author Tiziana Rancati
Author Andreas Rimner
Author Barry S. Rosenstein
Author Dirk De Ruysscher
Author Ahmed Salem
Author Claudia Sangalli
Author Petra Seibold
Author Paloma Sosa-Fajardo
Author Elena Sperk
Author Hilary Stobart
Author Holly Summersgill
Author Veerle Surmont
Author Paul Symonds
Author Begoña Taboada-Lorenzo
Author Christopher J. Talbot
Author Riccardo Valdagni
Author Ana Vega
Author Liv Veldeman
Author Marlon R. Veldwijk
Author Tim Ward
Author Adam Webb
Author Catharine M. L. West
Author Yolande Lievens
Abstract OBJECTIVES: Radiotherapy-induced toxicity may negatively impact health-related quality of life (HRQoL). This report investigates the impact of curative-intent radiotherapy on HRQoL and toxicity in early stage and locally-advanced non-small cell lung cancer patients treated with radiotherapy or chemo-radiotherapy enrolled in the observational prospective REQUITE study. MATERIALS AND METHODS: HRQoL was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire up to 2 years post radiotherapy. Eleven toxicities were scored by clinicians using the Common Terminology Criteria for Adverse Events (CTCAE) version 4. Toxicity scores were calculated by subtracting baseline values. Mixed model analyses were applied to determine statistical significance (p ? 0.01). Meaningful clinical important differences (MCID) were determined for changes in HRQoL. Analysis was performed on the overall data, different radiotherapy techniques, multimodality treatments and disease stages. RESULTS: Data of 510 patients were analysed. There was no significant change in HRQoL or its domains, except for deterioration in cognitive functioning (p = 0.01). Radiotherapy technique had no significant impact on HRQoL. The addition of chemotherapy was significantly associated with HRQoL over time (p <.001). Overall toxicity did not significantly change over time. Acute toxicities of radiation-dermatitis (p =.003), dysphagia (p =.002) and esophagitis (p <.001) peaked at 3 months and decreased thereafter. Pneumonitis initially deteriorated but improved significantly after 12 months (p =.011). A proportion of patients experienced meaningful clinically important improvements and deteriorations in overall HRQoL and its domains. In some patients, pre-treatment symptoms improved gradually. CONCLUSIONS: While overall HRQoL and toxicity did not change over time, some patients improved, whereas others experienced acute radiotherapy-induced toxicities and deteriorated HRQoL, especially physical and cognitive functioning. Patient characteristics, more so than radiotherapy technique and treatment modality, impact post-radiotherapy toxicity and HRQoL outcomes. This stresses the importance of considering the potential impact of radiotherapy on individuals' HRQoL, symptoms and toxicity in treatment decision-making.
Publication Lung Cancer (Amsterdam, Netherlands)
Volume 166
Pages 228-241
Date 2022-04
Journal Abbr Lung Cancer
Language eng
DOI 10.1016/j.lungcan.2022.03.010
ISSN 1872-8332
Library Catalog PubMed
Extra PMID: 35334417 PMCID: PMC9698940
Tags Carcinoma, Non-Small-Cell Lung, clinic, Humans, Lung Neoplasms, Prospective Studies, Quality of Life, Radiation Injuries, Surveys and Questionnaires
Date Added 2023/11/23 - 12:48:27
Date Modified 2024/12/15 - 11:22:36
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés